Arcoma

Arcoma FCF Growth

The Year-over-Year Free Cash Flow Growth of Arcoma (ARCOMA.ST) as of Oct 24, 2026 is 8.55 %. In the previous year, Year-over-Year Free Cash Flow Growth was -27.36 % — a change of -131.27% (higher).

FCF Growth

8.55 %

YoY

-131.27%

Last updated:

Year-over-Year Free Cash Flow Growth of Arcoma is 2025 8.55 % . Year-over-Year Free Cash Flow Growth of Arcoma was 2024 -27.36 % . It decreases by -131.27% higher compared to the previous year.

The Arcoma FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
92.76 SEK
Jan 1, 2019
96.79 SEK
Jan 1, 2020
-17,239.29 SEK
Jan 1, 2021
-26.06 SEK
Jan 1, 2022
28.95 SEK
Jan 1, 2023
481.95 SEK
Jan 1, 2024
-27.36 SEK
Jan 1, 2025
8.55 SEK
The Arcoma FCF Growth history
YEARFCF GrowthYoY
8.55 %-131.27%
-27.36 %-105.68%
481.95 %+1,564.51%
28.95 %-211.12%
-26.06 %-99.85%
-17,239.29 %-17,911.88%
96.79 %+4.34%
92.76 %-179.29%
-116.98 %-365.64%
44.04 %-176.47%
-57.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Year-over-Year Free Cash Flow Growth of Arcoma is 8.55 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Arcoma since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Arcoma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Arcoma

All Key Metrics — Arcoma